Oncology

The presence of ctDNA and CTCs in the plasma of the blood of women who have undergone chemotherapy prior to surgery for the treatment of triple-negative breast cancer (TNBC) are critical indicators in the prediction of disease recurrence and disease-free survival.

Since 2015, there has been an increase in the number of specialty pharmacies in the United States due to their potential of handling the complexities of cost and appropriate drug access and administration.

The human papillomavirus infection (HPV) vaccine should be administered in 2 doses for children between 9 and 12 years of age, according to updated guidelines from the American Cancer Society (ACS).

Early and frequent screenings for childhood cancer survivors could cut breast cancer mortality by well over half.

A potential correlation between processed food and breast cancer has been discovered.

At the completion of this activity, the participant will be able to determine appropriate treatment options for a patient with relapsed or refractory FL or MCL.

This cancer is characterized by scar tissue accumulation in the bone marrow, which leads to an insufficient quantity of normal blood cells.

Urothelial carcinoma accounts for approximately 90% of all bladder cancers and becomes increasingly challenging to treat as it spreads through the layers of the bladder wall.

The development and use of specialty pharmaceuticals have significantly affected global health care practices and costs.

Erlotinib taken with gemcitabine was approved by the FDA for locally advanced, inoperable, or metastatic pancreatic cancer in 2005.

According to the FDA, patients should be selected based on an FDA-approved companion diagnostic test.

One in 8 women will develop breast cancer within their lifetime, making it the most commonly diagnosed cancer among women.

A new study found disturbing evidence that black cancer survivors are more likely to face financial hardship on high deductible health plans than their white counterparts.

There has been growing evidence supporting new therapeutic approaches for this heterogenous group of diseases.

Pharmacy Times spoke with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, about how the drug niraparib could affect treatment options for patients with ovarian cancer.

Pembrolizumab has been approved by the FDA as a monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma.

Molecule binds and blocks a previously unknown opioid receptor in the brain, potentially revolutionizing pain, depression, and cancer treatment.

The objective of the study was to examine a large clinical dataset of LGSC through the Ovarian Cancer Association Consortium, with the primary goal of identifying factors that affect survival.

Women diagnosed with breast cancer while breastfeeding may receive treatments that decrease milk production or are contraindicated.

A study presented at the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer showed menstrual cups may provide a novel, less invasive, and more comfortable approach to the diagnosis of endometrial cancer.

Oncology drugs have especially fallen victim to chronic shortages, consequently affecting the availability of substitute agents.

With new and varying options for maintenance therapy in patients with ovarian cancer, patients may express a preference when discussing potential maintenance treatments and their adverse effects.

Researchers found that replacing 30 minutes of inactivity with exercise significantly reduces the risk of cancer-related death.

The intent of the study was to bring awareness to the medical and nonmedical financial hardships of cancer and how they can impact the use of preventive services, since there is little research available to evaluate this topic, according to the study authors.

Pembrolizumab (Keytruda, Merck) monotherapy approved for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

The most common adverse reactions observed in the monarchE phase 3 trial include diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, vomiting, anemia, alopecia, decreased appetite, and leukopenia.

Lurbinectedin (Zepzelca) approved based on overall response rate and duration of response in patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

Although many hubs offer similar services, no two specialty pharmacy hubs and no two hub programs are entirely alike.